What does Gooreind Pharma do?

Gooreind Pharma is a logistics company in Wuustwezel. Private Limited, started on 6 December 2004, 1 establishment.

What is the address of Gooreind Pharma?

The registered office of Gooreind Pharma is located at Theo Verellenlaan 70, 2990 Wuustwezel.

Is Gooreind Pharma still active?

Yes. According to the CBE (30 October 2026) Gooreind Pharma is active, legal situation “Normale toestand”, started on 6 December 2004.

Is Gooreind Pharma registered on Peppol?

Yes, Gooreind Pharma is registered on the Peppol network with ID 0208:0870403170.

What is the enterprise number of Gooreind Pharma?

The enterprise number of Gooreind Pharma is BE0870403170.

When was Gooreind Pharma founded?

Gooreind Pharma was founded on 6 December 2004.

Who are the directors of Gooreind Pharma?

According to the 2025 annual accounts, the directors of Gooreind Pharma are: Apotheek Dolhain BV, Kempen Pharma BV.

Is Gooreind Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 December 2004; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Gooreind Pharma make in 2025?

Gooreind Pharma posted a profit after taxes of € 59,344 in financial year 2025.

What is the revenue of Gooreind Pharma?

As a small company, Gooreind Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 487,006.

How much does an employee at Gooreind Pharma earn?

The average wage cost per full-time employee at Gooreind Pharma was € 77,600 in 2025: staff costs of € 341,331 for 4.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Gooreind Pharma have?

According to the 2025 annual accounts, Gooreind Pharma has 4.4 full-time equivalents (FTE).

Does Gooreind Pharma have a website?

Yes, Gooreind Pharma has a website at gooreindpharma.be.

Gooreind Pharma (Private Limited) - Wuustwezel

Dossier Gooreind Pharma, printed on 30 October 2026 from databakkes.be/en/0870403170/gooreind-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Gooreind Pharma from Wuustwezel, company number BE0870403170, closed financial year 2025 with a result of € 59,344 after tax. For that financial year Gooreind Pharma recorded a gross margin of € 487,006 and equity of € 390,026. Compared with financial year 2024, the result moved from € 57,125 to € 59,344. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 4, 2026.

What it is worth Healthy

€ 390,026

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 59,344

▲ 4% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 100,334

▲ 25% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 60,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

4.4

▼ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 341,331

▲ 8% vs 2024

€ 77,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,291

▼ 66% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 225,357

▼ 15% vs 2024

€ 39,981 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 73,031

▼ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 42,678

▲ 9% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 259,837 Gross margin 2022: € 259,837 First fiscal year in the series	€ 432,845 Gross margin 2023: € 432,845 ▲ 67% vs 2022 (€ 259,837) Favourable step	€ 460,528 Gross margin 2024: € 460,528 ▲ 6% vs 2023 (€ 432,845) Favourable step	€ 487,006 Gross margin 2025: € 487,006 ▲ 6% vs 2024 (€ 460,528) Favourable step	▲ 6%
Profit after taxes	€ 19,176 Profit after taxes 2022: € 19,176 First fiscal year in the series	€ 35,042 Profit after taxes 2023: € 35,042 ▲ 83% vs 2022 (€ 19,176) Favourable step	€ 57,125 Profit after taxes 2024: € 57,125 ▲ 63% vs 2023 (€ 35,042) Favourable step	€ 59,344 Profit after taxes 2025: € 59,344 ▲ 4% vs 2024 (€ 57,125) Favourable step	▲ 4%
Equity	€ 473,514 Equity 2022: € 473,514 First fiscal year in the series	€ 433,557 Equity 2023: € 433,557 ▼ 8% vs 2022 (€ 473,514) Unfavourable step	€ 390,682 Equity 2024: € 390,682 ▼ 10% vs 2023 (€ 433,557) Unfavourable step	€ 390,026 Equity 2025: € 390,026 Unchanged (€ 390,682) Unfavourable step
Total debts	€ 447,711 Total debts 2022: € 447,711 First fiscal year in the series	€ 490,560 Total debts 2023: € 490,560 ▲ 10% vs 2022 (€ 447,711) Unfavourable step	€ 488,892 Total debts 2024: € 488,892 Unchanged (€ 490,560) Favourable step	€ 401,216 Total debts 2025: € 401,216 ▼ 18% vs 2024 (€ 488,892) Favourable step	▼ 18%
Cash	€ 105,577 Cash 2022: € 105,577 First fiscal year in the series	€ 142,543 Cash 2023: € 142,543 ▲ 35% vs 2022 (€ 105,577) Favourable step	€ 80,537 Cash 2024: € 80,537 ▼ 44% vs 2023 (€ 142,543) Unfavourable step	€ 100,334 Cash 2025: € 100,334 ▲ 25% vs 2024 (€ 80,537) Favourable step	▲ 25%
Land & buildings	-	€ 54,542 Land & buildings 2023: € 54,542 First fiscal year in the series	€ 47,342 Land & buildings 2024: € 47,342 ▼ 13% vs 2023 (€ 54,542) Unchanged	€ 40,142 Land & buildings 2025: € 40,142 ▼ 15% vs 2024 (€ 47,342) Unchanged	▼ 15%
Retained profit	€ 454,314 Retained profit 2022: € 454,314 First fiscal year in the series	€ 414,357 Retained profit 2023: € 414,357 ▼ 9% vs 2022 (€ 454,314) Unfavourable step	€ 371,482 Retained profit 2024: € 371,482 ▼ 10% vs 2023 (€ 414,357) Unfavourable step	€ 370,826 Retained profit 2025: € 370,826 Unchanged (€ 371,482) Unfavourable step
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 75,000 Dividend 2023: € 75,000 Unchanged (€ 0) Unchanged	€ 100,000 Dividend 2024: € 100,000 ▲ 33% vs 2023 (€ 75,000) Unchanged	€ 60,000 Dividend 2025: € 60,000 ▼ 40% vs 2024 (€ 100,000) Unchanged	▼ 40%
Bank debt	€ 342,730 Bank debt 2022: € 342,730 First fiscal year in the series	€ 304,029 Bank debt 2023: € 304,029 ▼ 11% vs 2022 (€ 342,730) Favourable step	€ 264,906 Bank debt 2024: € 264,906 ▼ 13% vs 2023 (€ 304,029) Favourable step	€ 225,357 Bank debt 2025: € 225,357 ▼ 15% vs 2024 (€ 264,906) Favourable step	▼ 15%
Balance sheet total	€ 921,226 Balance sheet total 2022: € 921,226 First fiscal year in the series	€ 924,117 Balance sheet total 2023: € 924,117 Unchanged (€ 921,226) Unchanged	€ 879,574 Balance sheet total 2024: € 879,574 ▼ 5% vs 2023 (€ 924,117) Unchanged	€ 791,241 Balance sheet total 2025: € 791,241 ▼ 10% vs 2024 (€ 879,574) Unchanged	▼ 10%
Employees (FTE)	3.3 Employees (FTE) 2022: 3.3 First fiscal year in the series	4.3 Employees (FTE) 2023: 4.3 ▲ 1 vs 2022 (3.3) Unchanged	4.6 Employees (FTE) 2024: 4.6 ▲ 0.3 vs 2023 (4.3) Unchanged	4.4 Employees (FTE) 2025: 4.4 ▼ 0.2 vs 2024 (4.6) Unchanged	▼ 0.2

Key figures of Gooreind Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Gooreind Pharma?

What happened at Gooreind Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 4, 2026 New annual accounts for financial year 2025: profit of € 59,344 (▲ 4% vs 2024). filed late Source: NBB ↗
2017 Apotheek Dolhain BV became a director. NBB
2017 Kempen Pharma BV became a director. NBB
Dec 6, 2004 Start of the company according to the CBE. KBO
Nov 29, 2004 New establishment in Wuustwezel. KBO

In short

From € 19,176 profit in 2022 to € 59,344 profit in 2025.

Paid € 46,114 in corporate taxes since 2022.

Best year ever: 2025, with € 59,344 profit.

On average € 110,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

CATANT 64.6%

KEMPEN PHARMA 35.4%

The stake of CATANT, KEMPEN PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Gooreind Pharma

Behind Gooreind Pharma are Apotheek Dolhain BV and Kempen Pharma BV. The shares are held by CATANT (64.6%) and KEMPEN PHARMA (35.4%).

Directors

According to the 2025 annual accounts

Apotheek Dolhain BV

Director · represented by Sleeubus Inge

since 2017

Kempen Pharma BV

Director · represented by Kempen Ineke

Also active at: MEDIGREX

since 2017

Shareholders

CATANT

64.6%

KEMPEN PHARMA

35.4%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Theo Verellenlaan 70

2990 Wuustwezel

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS gooreindpharma.be

About

Technologies

AvadaFont AwesomeNginxPHPWordPressjQuery

Hosting & Email

Email provider

Google Workspace

Hosting

COMBELL-AS, BE

Website info

HTTPS Ja

Languages NL

Features

Webshop Contact page

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ IPv6

Details

Company number

0870.403.170

VAT number

BE 0870.403.170

Registered office

Theo Verellenlaan 70, 2990 Wuustwezel

Names & denominations

Gooreind Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

6 December 2004

Peppol

Active · Active since 27 Nov 2025

Contact

gooreindpharma.be

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Gooreind Pharma

Financials

What happened to Gooreind Pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions